Profund Advisors LLC lifted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 73.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,638 shares of the biotechnology company’s stock after purchasing an additional 5,338 shares during the period. Profund Advisors LLC’s holdings in United Therapeutics were worth $4,026,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Symmetry Investments LP purchased a new stake in United Therapeutics in the second quarter worth $669,000. Ensign Peak Advisors Inc lifted its position in shares of United Therapeutics by 27.2% during the 2nd quarter. Ensign Peak Advisors Inc now owns 33,677 shares of the biotechnology company’s stock valued at $10,728,000 after buying an additional 7,205 shares during the last quarter. Pacer Advisors Inc. grew its stake in shares of United Therapeutics by 19.6% during the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock worth $178,972,000 after acquiring an additional 92,240 shares during the period. Skandinaviska Enskilda Banken AB publ increased its holdings in United Therapeutics by 47.6% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 87,370 shares of the biotechnology company’s stock worth $27,832,000 after acquiring an additional 28,192 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. raised its stake in United Therapeutics by 14.0% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 42 shares during the period. Institutional investors own 94.08% of the company’s stock.
United Therapeutics Stock Up 0.5 %
Shares of NASDAQ UTHR opened at $353.00 on Friday. The business has a 50-day moving average of $339.19 and a 200-day moving average of $291.68. The firm has a market capitalization of $15.66 billion, a price-to-earnings ratio of 16.69, a PEG ratio of 1.25 and a beta of 0.57. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $366.08.
Insider Activity at United Therapeutics
In other news, CFO James Edgemond sold 7,785 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the transaction, the chief financial officer now directly owns 2,615 shares in the company, valued at approximately $947,597.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO James Edgemond sold 7,785 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the sale, the chief financial officer now directly owns 2,615 shares in the company, valued at approximately $947,597.55. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 269 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $45,293.30. The disclosure for this sale can be found here. Insiders have sold a total of 110,922 shares of company stock valued at $36,541,398 over the last 90 days. 12.50% of the stock is owned by insiders.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on UTHR. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. UBS Group lifted their price objective on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research note on Monday, July 8th. TD Cowen increased their target price on United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Bank of America reduced their price target on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. Finally, StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $350.36.
Get Our Latest Research Report on UTHR
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Further Reading
- Five stocks we like better than United Therapeutics
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- ETF Screener: Uses and Step-by-Step Guide
- MarketBeat Week in Review – 9/16 – 9/20
- 3 Tickers Leading a Meme Stock Revival
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.